Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TOBRADEX · 1 trial · 1 indication
Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject's right eye for each treatment period.
| Arm | Type | Description |
|---|---|---|
| Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension | EXPERIMENTAL | Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension |
| TOBREX® Ophthalmic Solution | ACTIVE_COMPARATOR | TOBREX® Ophthalmic Solution |
| TOBRADEX® Ophthalmic Suspension | ACTIVE_COMPARATOR | TOBRADEX® Ophthalmic Suspension |
| Name | Type | Description |
|---|---|---|
| TOBRADEX Ophthalmic Suspension | DRUG | TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline |
| Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension | DRUG | Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline |
| TOBREX Ophthalmic Solution | DRUG | TOBREX Ophthalmic Solution 1 drop each eye at baseline |
Inclusion: * Visual Acuity (VA) of 0.6 logMAR or better * Tear meniscus height of ≥ 0.3mm at Visit 1. * No concomitant topical ocular medications, including artificial tears, during the study period Exclusion * ocular hypertension, iritis or uveitis, glaucoma * ocular surgery, intraocular surgery...
TOBRADEX is an investigational small molecule being studied for the treatment of Dry Eye. It is currently in Phase 1 clinical development. The drug is being developed by Alcon Inc. (NYSE: ALC) for use in ophthalmology.
The molecular target of TOBRADEX has not been disclosed. It is a small molecule being investigated for Dry Eye, but its specific mechanism of action is not publicly available at this time.
TOBRADEX is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is focused on ophthalmology products, and TOBRADEX is one of its investigational assets for Dry Eye.
TOBRADEX is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for Dry Eye, and the Phase 1 trial has been completed.
TOBRADEX has one completed Phase 1 clinical trial, NCT00695435, titled 'Tobramycin Tear Concentrations.' The study enrolled 21 participants with Dry Eye in the United States. It was a randomized, double-blind, active-controlled trial involving healthy volunteers aged 18 years and older.
TOBRADEX is a combination product that contains tobramycin, an antibiotic, and dexamethasone, a corticosteroid. While tobramycin is one of its active ingredients, TOBRADEX is a distinct drug product. The Phase 1 trial for Dry Eye measured tobramycin tear concentrations.